Recormon is indicated for: Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis.
Treatment of symptomatic renal anemia in patients not yet undergoing dialysis.
Prevention of anemia of prematurity in infants with a birth weight of 750g to 1500 g and a gestational age of less than 34 weeks.
Treatment of anemia in adult patients with solid tumours and treated with platinum-based chemotherapy prone to induce anemia (cisplatin: 75 mg/m2/cycle; carboplatin: 350 mg/m2/cycle).
Treatment of symptomatic anemia in adult patients with multiple myeloma, low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia, who have a relative erythropoietin deficiency and are receiving anti-tumor therapy. Deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.
Increasing the yield of autologous blood from patients in a pre-donation program.
Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10 to 13 g/dl [6.21 to 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).